Management of Elevated LDL‑C and Hypertriglyceridemia in Adults

For adults with elevated LDL‑C and/or hypertriglyceridemia, initiate high‑intensity statin therapy immediately if any of the following are present: established ASCVD, diabetes age 40–75 years with additional risk factors, LDL‑C ≥190 mg/dL, or 10‑year ASCVD risk ≥20%; for moderate hypertriglyceridemia (200–499 mg/dL) without these criteria, start moderate‑intensity statin therapy after shared decision‑making, and for severe hypertriglyceridemia (≥500 mg/dL), initiate fenofibrate immediately to prevent pancreatitis before addressing LDL‑C. 1, 2

Step 1: Initial Assessment & Risk Stratification

Obtain Baseline Lipid Panel

Measure fasting total cholesterol, LDL‑C, HDL‑C, and triglycerides at diagnosis, before starting therapy, and annually while on treatment. 1, 2
In adults <40 years not receiving lipid‑lowering drugs, repeat the lipid panel at least every 5 years or sooner if new risk factors appear. 1, 2

Calculate 10‑Year ASCVD Risk

Use the Pooled Cohort Equations for patients without diabetes or established ASCVD to guide treatment intensity. 1, 2
The calculator has limited utility in persons with diabetes because it does not account for diabetes duration or complications such as albuminuria. 1

Identify Secondary Causes

Check hemoglobin A1c and fasting glucose; optimizing glycemic control can lower triglycerides by 20–50% independent of lipid medications. 2, 3
Measure TSH to exclude hypothyroidism, which must be treated before expecting full lipid‑lowering response. 2, 3
Obtain a detailed alcohol history; even 1 oz daily can raise triglycerides by 5–10%, and complete abstinence is mandatory when triglycerides approach 500 mg/dL. 2, 3
Review medications that raise triglycerides (thiazide diuretics, beta‑blockers, oral estrogen, corticosteroids, antiretrovirals, atypical antipsychotics) and discontinue or substitute when possible. 2, 3
Assess renal (creatinine, eGFR) and hepatic (AST, ALT) function, as chronic kidney or liver disease contributes to dyslipidemia and influences drug dosing. 2, 3

Step 2: Lifestyle Modifications (Foundation for All Patients)

Dietary Pattern

Adopt a Mediterranean or DASH dietary pattern rich in vegetables, fruits, whole grains, legumes, and non‑tropical vegetable oils. 1, 2
Limit saturated fat to <7% of total calories and eliminate trans fats completely. 1, 2
Increase intake of viscous fiber (≈10–25 g/day), plant stanols/sterols (≈2 g/day), and omega‑3 fatty acids from fatty fish (≥2 servings/week). 1, 2

Weight & Physical Activity

Pursue 5–10% body‑weight reduction, which produces a 20% decrease in triglycerides—the most effective single lifestyle measure. 2, 3
Perform ≥150 minutes/week of moderate‑intensity aerobic activity (or ≥75 minutes/week of vigorous activity), which reduces triglycerides by ≈11%. 1, 2

Triglyceride‑Specific Dietary Modifications

Mild‑to‑moderate hypertriglyceridemia (150–499 mg/dL): Restrict added sugars to <6% of total calories (≈30 g on a 2,000‑kcal diet), limit total fat to 30–35% of calories, and increase soluble fiber to >10 g/day. 2, 3
Severe hypertriglyceridemia (500–999 mg/dL): Restrict total fat to 20–25% of calories, eliminate all added sugars, and enforce complete alcohol abstinence. 2, 3
Very severe hypertriglyceridemia (≥1,000 mg/dL): Implement extreme fat restriction to 10–15% of calories (or <5% until triglycerides fall below 1,000 mg/dL). 2, 3

Step 3: Statin Therapy Initiation

High‑Intensity Statin Indications (Start Immediately)

Established ASCVD (any age): Prescribe atorvastatin 40–80 mg or rosuvastatin 20–40 mg daily to achieve LDL‑C <70 mg/dL and ≥50% reduction from baseline. 1, 4
Diabetes age 40–75 years with ≥1 additional ASCVD risk factor (e.g., hypertension, smoking, CKD, albuminuria, premature family history): Use high‑intensity statin to achieve LDL‑C <70 mg/dL and ≥50% reduction. 1, 4
LDL‑C ≥190 mg/dL (≥4.9 mmol/L): Initiate high‑intensity statin immediately without calculating 10‑year ASCVD risk, aiming for ≥50% LDL‑C reduction. 1, 2
10‑year ASCVD risk ≥20%: Use high‑intensity statin to achieve ≥50% LDL‑C reduction. 1, 2

Moderate‑Intensity Statin Indications

Diabetes age 40–75 years without additional ASCVD risk factors: Use atorvastatin 10–20 mg, rosuvastatin 5–10 mg, simvastatin 20–40 mg, or pravastatin 40–80 mg daily. 1, 4
10‑year ASCVD risk 7.5%–<20% (intermediate risk): Start moderate‑intensity statin; upgrade to high‑intensity if risk‑enhancing factors (e.g., premature CHD family history, CKD, metabolic syndrome, triglycerides ≥175 mg/dL, inflammatory disease) are present. 1, 2
10‑year ASCVD risk 5%–<7.5% (borderline risk): Consider moderate‑intensity statin only if risk‑enhancing factors exist; coronary artery calcium score ≥100 (or ≥75th percentile) may justify statin initiation. 1, 2

Special Populations

Diabetes age 20–39 years with additional ASCVD risk factors: Consider statin after shared decision‑making. 1, 4
Age >75 years with diabetes: Continue current statin if already on therapy; if initiating, consider moderate‑intensity statin after shared decision‑making. 1, 4
Pregnancy: Statin therapy is absolutely contraindicated. 1, 4

Statin Dosing Reference

High‑Intensity (≥50% LDL‑C reduction)	Moderate‑Intensity (30–49% LDL‑C reduction)
Atorvastatin 40–80 mg	Atorvastatin 10–20 mg
Rosuvastatin 20–40 mg	Rosuvastatin 5–10 mg
	Simvastatin 20–40 mg
	Pravastatin 40–80 mg
	Lovastatin 40 mg
	Fluvastatin XL 80 mg
	Pitavastatin 1–4 mg

1, 4, 5

Step 4: Management of Severe Hypertriglyceridemia (≥500 mg/dL)

Immediate Pharmacologic Intervention

Initiate fenofibrate 54–160 mg daily immediately to prevent acute pancreatitis, irrespective of LDL‑C level or cardiovascular risk. 2, 3
Fenofibrate reduces triglycerides by 30–50%; statins alone provide only 10–30% reduction, which is insufficient to prevent pancreatitis at this level. 2, 3, 6
Do not start with statin monotherapy when triglycerides are ≥500 mg/dL; fibrates must be initiated first. 2, 3

Dietary Interventions

Restrict total dietary fat to 20–25% of calories for triglycerides 500–999 mg/dL, or to 10–15% (or <5% until triglycerides fall below 1,000 mg/dL) for very severe hypertriglyceridemia. 2, 3
Eliminate all added sugars and enforce complete alcohol abstinence. 2, 3

Sequential Treatment

Once triglycerides fall <500 mg/dL with fenofibrate, reassess LDL‑C and add statin therapy if LDL‑C is elevated or cardiovascular risk is high. 2, 3
Target LDL‑C <100 mg/dL (or <70 mg/dL for very high‑risk patients) and non‑HDL‑C <130 mg/dL. 2, 3

Step 5: Add‑On Therapies for Persistent Elevation

Ezetimibe (First‑Line Add‑On for LDL‑C)

Add ezetimibe 10 mg daily when LDL‑C remains ≥70 mg/dL on maximally tolerated statin in:
- Diabetic patients aged 40–75 years at higher cardiovascular risk. 1, 2
- Patients with established ASCVD (very high risk). 1, 2
- Individuals with 10‑year ASCVD risk ≥20% who achieve <50% LDL‑C reduction on maximally tolerated statin. 2
Ezetimibe provides an additional 13–20% LDL‑C reduction and has proven cardiovascular benefit when added to statins. 2, 7

PCSK9 Inhibitors (Second‑Line Add‑On for LDL‑C)

Add a PCSK9 inhibitor (evolocumab or alirocumab) when LDL‑C ≥70 mg/dL despite maximally tolerated statin + ezetimibe in:
- Very high‑risk patients with established ASCVD. 1, 2
- Diabetic patients aged 40–75 years with multiple ASCVD risk factors. 1, 2
Long‑term safety (>3 years) is uncertain, and cost‑effectiveness is low at mid‑2018 list prices. 1

Icosapent Ethyl (Prescription EPA for Triglycerides)

Add icosapent ethyl 2 g twice daily (total 4 g/day) when triglycerides remain ≥150 mg/dL after 3 months of optimized lifestyle and statin therapy in patients with:
- Established cardiovascular disease or
- Diabetes with ≥2 additional cardiovascular risk factors (e.g., hypertension, smoking, family history, age >50 y men/ >60 y women, CKD). 2, 3, 8
The REDUCE‑IT trial demonstrated a 25% relative risk reduction in major adverse cardiovascular events (NNT = 21 over 4.9 years). 2, 3, 8
Icosapent ethyl is the only triglyceride‑lowering agent FDA‑approved for cardiovascular risk reduction. 2, 3, 8
Monitor for atrial fibrillation (incidence 3.1% vs 2.1% with placebo). 2, 3

Fenofibrate (When Icosapent Ethyl Criteria Not Met)

Add fenofibrate 54–160 mg daily if triglycerides remain >200 mg/dL after 3 months of optimized lifestyle and statin therapy and the patient does not meet icosapent ethyl criteria. 2, 3
When combined with statins, use fenofibrate (not gemfibrozil) because it does not inhibit statin glucuronidation and has a superior safety profile. 2, 3
Consider lower statin doses (atorvastatin ≤20 mg or rosuvastatin ≤10 mg) in patients >65 years or with renal impairment to minimize myopathy risk. 2, 3

Bempedoic Acid (Statin‑Intolerant Patients)

For statin‑intolerant diabetic patients, use bempedoic acid as an alternative cholesterol‑lowering agent to reduce cardiovascular events. 2, 8

Step 6: Monitoring Strategy

Lipid Panel Monitoring

Re‑measure fasting lipid panel 4–12 weeks after initiating or changing any statin or lipid‑lowering therapy to verify response and adherence. 1, 2
Perform annual lipid monitoring once the regimen is stable. 1, 2

Safety Monitoring

Monitor for muscle symptoms and obtain baseline and follow‑up creatine kinase levels when combining fenofibrate with statins, especially in patients >65 years or with renal disease. 2, 3
Check renal function at baseline, at 3 months, and then every 6 months while on fenofibrate; adjust dose if eGFR 30–59 mL/min/1.73 m² (max 54 mg daily) and avoid use if eGFR <30 mL/min/1.73 m². 2, 3
Monitor hepatic aminotransferases at baseline and periodically during statin therapy; if serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue statin. 1, 5

Step 7: Treatment Goals

LDL‑C Targets

Very high‑risk ASCVD (history of multiple major ASCVD events or 1 major event + multiple high‑risk conditions): LDL‑C <70 mg/dL (1.8 mmol/L) and ≥50% reduction from baseline. 1, 2
Established ASCVD or diabetes with multiple risk factors: LDL‑C <70 mg/dL and ≥50% reduction. 1, 2, 4
Moderate‑to‑high risk (10‑year ASCVD risk ≥7.5% or diabetes without additional risk factors): LDL‑C <100 mg/dL. 1, 2
Low risk (10‑year ASCVD risk <7.5%): LDL‑C <130 mg/dL. 1, 2

Triglyceride Targets

Primary goal: Reduce triglycerides to <200 mg/dL (ideally <150 mg/dL) to lower cardiovascular risk. 2, 3, 8
Severe hypertriglyceridemia: Achieve rapid reduction to <500 mg/dL to eliminate pancreatitis risk. 2, 3

Non‑HDL‑C Target

Achieve non‑HDL‑C <130 mg/dL (calculated as total cholesterol minus HDL‑C) as a secondary target when triglycerides are elevated. 1, 2, 3

HDL‑C Goals

HDL‑C >40 mg/dL for men and >50 mg/dL for women. 1, 2

Critical Pitfalls to Avoid

Statin Therapy Errors

Do not delay statin initiation while attempting lifestyle modifications alone in high‑risk patients (ASCVD risk ≥7.5%, diabetes, established ASCVD); both should be started concurrently. 2, 3, 4
Do not discontinue statins because of intolerance without first trying alternative statins, lower doses, or intermittent dosing schedules; even extremely low, less‑than‑daily statin doses provide cardiovascular benefit. 1, 4
Do not base statin intensity in diabetic patients aged 40–75 years solely on baseline LDL‑C; incorporate the presence of additional ASCVD risk factors. 1, 4

Triglyceride Management Errors

Do not start with statin monotherapy when triglycerides are ≥500 mg/dL; fibrates must be initiated first to prevent pancreatitis. 2, 3
Do not overlook secondary causes (uncontrolled diabetes, hypothyroidism, excess alcohol, offending medications); correcting these can lower triglycerides by 20–50% and may obviate the need for additional lipid agents. 2, 3
Do not combine gemfibrozil with statins; fenofibrate has a markedly better safety profile with lower myopathy risk when combined with statins. 2, 3
Do not rely on over‑the‑counter fish‑oil supplements for cardiovascular benefit; only prescription icosapet ethyl has proven outcome data. 2, 3

Add‑On Therapy Errors

Do not add fibrates or omega‑3 agents before completing at least 3 months of intensive lifestyle and statin therapy (unless triglycerides exceed 500 mg/dL). 2, 3
Do not use niacin; it showed no cardiovascular benefit when added to statin therapy and increased risk of new‑onset diabetes and gastrointestinal disturbances. 2, 3, 8

What is the step‑by‑step management plan for an adult with elevated low‑density lipoprotein cholesterol and/or hypertriglyceridemia, including indications for statin therapy intensity, add‑on agents, and lifestyle modifications?

Help us tailor your experience